tiprankstipranks
Trending News
More News >
CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
Hong Kong Market
Advertisement

CANbridge Pharmaceuticals Inc. (1228) AI Stock Analysis

Compare
0 Followers

Top Page

HK

CANbridge Pharmaceuticals Inc.

(1228)

Rating:50Neutral
Price Target:
HK$1.00
▲(16.28%Upside)
The stock's overall score is heavily impacted by poor financial performance due to significant operational losses and negative equity. Despite some short-term technical momentum, the overbought condition suggests caution. Valuation metrics are unappealing, with a negative P/E ratio highlighting unprofitability.

CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)

CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model

Company DescriptionCANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, an artificially engineered antibody-like fully human fusion protein for the treatment of glioblastoma multiforme; CAN108, an orally absorbed reversible inhibitor of the ileal bile acid transporter to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 being developed for the treatment of complement-mediated diseases; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid. The company was founded in 2012 and is headquartered in Beijing, China.
How the Company Makes MoneyCANbridge Pharmaceuticals generates revenue through multiple streams, primarily driven by the commercialization and sales of its proprietary and in-licensed pharmaceutical products. The company collaborates with global industry leaders to license and co-develop innovative therapies, enabling it to broaden its portfolio and market reach. Revenue is also derived from strategic partnerships, which may include milestone payments and royalties from out-licensed products. Additionally, CANbridge invests in research and development to advance its pipeline, which has the potential to create future revenue streams as these candidates progress through clinical trials and into the market.

CANbridge Pharmaceuticals Inc. Financial Statement Overview

Summary
CANbridge Pharmaceuticals Inc. faces significant financial hurdles with high operational losses and negative equity. The ongoing cash flow struggles and reliance on financing highlight challenges in achieving financial sustainability in the competitive biotechnology sector.
Income Statement
45
Neutral
The company shows a declining revenue trend with significant net losses. Gross profit margins are positive but are overshadowed by high negative EBIT and net profit margins due to substantial expenditures. Revenue growth has been inconsistent, demonstrating challenges in achieving sustainable growth in a competitive industry.
Balance Sheet
30
Negative
The company's balance sheet reflects high leverage with negative equity, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a risk in volatile markets. Despite a relatively low asset base, the company struggles with substantial liabilities, indicating potential liquidity issues.
Cash Flow
40
Negative
Operating and free cash flows are consistently negative, indicating challenges in generating positive cash flow from operations. The company's reliance on external financing is evident, and the cash flow to net income ratios highlight inefficiencies in converting profits into cash, exacerbating financial strain.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue85.10M102.87M78.97M31.16M12.03M
Gross Profit54.30M64.16M48.89M18.78M6.88M
EBITDA-328.69M-341.43M-454.63M-1.06B-824.41M
Net Income-442.62M-378.84M-483.48M-1.08B-846.04M
Balance Sheet
Total Assets116.81M395.36M702.04M892.52M586.36M
Cash, Cash Equivalents and Short-Term Investments10.50M137.49M451.16M745.82M360.80M
Total Debt135.78M141.93M155.28M52.10M46.90M
Total Liabilities591.30M435.15M393.49M199.13M2.33B
Stockholders Equity-474.49M-39.79M308.56M693.39M-1.75B
Cash Flow
Free Cash Flow-122.50M-319.09M-315.76M-592.40M-305.13M
Operating Cash Flow-122.39M-278.23M-280.98M-587.07M-151.65M
Investing Cash Flow13.93M-26.86M-34.79M126.09M-153.48M
Financing Cash Flow-18.57M-28.02M-20.70M854.31M679.26M

CANbridge Pharmaceuticals Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.86
Price Trends
50DMA
0.28
Positive
100DMA
0.22
Positive
200DMA
0.21
Positive
Market Momentum
MACD
0.15
Negative
RSI
86.94
Negative
STOCH
82.45
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Positive. The current price of 0.86 is above the 20-day moving average (MA) of 0.46, above the 50-day MA of 0.28, and above the 200-day MA of 0.21, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 86.94 is Negative, neither overbought nor oversold. The STOCH value of 82.45 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1228.

CANbridge Pharmaceuticals Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
€6.38B19.89-1.30%2.25%-0.16%-45.39%
59
Neutral
HK$1.17B-41.34%-10.78%24.88%
57
Neutral
HK$790.37M-32.59%-79.65%37.50%
54
Neutral
HK$596.29M-266.90%31.23%
50
Neutral
HK$361.11M
-18.57%-14.06%
48
Neutral
HK$434.52M
-1.73%-689.53%
36
Underperform
HK$796.92M-41.20%85.23%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1228
CANbridge Pharmaceuticals Inc.
0.83
0.48
137.14%
HK:9939
Kintor Pharmaceutical Ltd
2.18
1.13
107.62%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.95
1.10
59.46%
HK:2197
Clover Biopharmaceuticals Ltd.
0.38
0.08
26.67%
HK:2257
Sirnaomics Ltd.
5.70
0.85
17.53%
HK:6628
Transcenta Holding Limited
1.92
0.50
35.21%

CANbridge Pharmaceuticals Inc. Corporate Events

CANbridge Pharmaceuticals Relocates Hong Kong Office to Enhance Operations
Jul 11, 2025

CANbridge Pharmaceuticals Inc. has announced a change in its principal place of business in Hong Kong, moving to the 40th Floor, Dah Sing Financial Centre, effective July 11, 2025. This relocation reflects the company’s strategic efforts to enhance its operational capabilities and strengthen its presence in the region, potentially impacting its stakeholders by positioning the company for future growth and development.

CANbridge Pharmaceuticals Strengthens Board with New Appointments
Jun 30, 2025

CANbridge Pharmaceuticals Inc. has announced the appointment of Ms. Zhao Wei as a non-executive director and a member of the remuneration committee, effective June 30, 2025. This appointment is part of a broader change in the composition of the board committees, which also includes the addition of Dr. Lan Hu to the Nomination and Corporate Governance Committee to meet gender diversity requirements. These changes are expected to enhance the company’s governance and strategic direction.

CANbridge Pharmaceuticals Announces Board Composition and Roles
Jun 30, 2025

CANbridge Pharmaceuticals Inc. has announced the composition of its board of directors and their respective roles within the company. This update highlights the leadership structure and the committees each director is involved in, reflecting the company’s commitment to strong governance and strategic oversight.

CANbridge Pharmaceuticals Enhances Governance with New Committee
Jun 30, 2025

CANbridge Pharmaceuticals Inc. has established a Nomination and Corporate Governance Committee, as resolved by its Board of Directors on June 21, 2021. This move is part of the company’s efforts to enhance its corporate governance structure, which could potentially strengthen its industry positioning and provide better oversight for stakeholders.

CANbridge Pharmaceuticals Secures Shareholder Approval at AGM
Jun 27, 2025

CANbridge Pharmaceuticals Inc. announced that all resolutions, except one which was withdrawn, were approved at their Annual General Meeting held on June 27, 2025. The resolutions included re-electing directors, authorizing board remuneration, reappointing the auditor, and granting mandates for share issuance and repurchase. This outcome reflects strong shareholder support and positions the company for continued strategic initiatives in its industry.

CANbridge Pharmaceuticals Announces Board Changes and AGM Resolution Withdrawal
Jun 25, 2025

CANbridge Pharmaceuticals Inc. announced the resignation of Dr. Fangxin Li as a non-executive director and member of the remuneration committee, effective June 25, 2025, due to changes in his work arrangements. This resignation has resulted in the remuneration committee falling below its required number of members, prompting the company to seek a suitable replacement. Additionally, the company has withdrawn an ordinary resolution related to Dr. Li’s proposed re-election at the upcoming annual general meeting, while all other meeting details remain unchanged.

CANbridge Pharmaceuticals to Hold Virtual AGM with Key Resolutions on June 27, 2025
Jun 6, 2025

CANbridge Pharmaceuticals Inc. has announced that its annual general meeting (AGM) will be held virtually on June 27, 2025. The meeting will cover several key resolutions, including the re-election of board members, the re-appointment of the company’s auditor, and the authorization for directors to issue additional shares. These decisions are crucial for the company’s governance and financial strategies, potentially impacting its market operations and shareholder value.

CANbridge Pharmaceuticals Gains Approval for Gaucher Disease Treatment in China
May 20, 2025

CANbridge Pharmaceuticals Inc. announced that its product, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval in the PRC for treating type I and III Gaucher disease. This approval marks a significant milestone as Gaurunning is the first domestically developed enzyme replacement therapy for these conditions, potentially enhancing medication accessibility for patients in China and strengthening CANbridge’s position in the rare disease treatment market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025